Hyperbaric oxygenation for experimental bladder tumor. II. Hyperbaric oxygenation in combination with chemotherapy in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors.
Two series of experiments were conducted to ascertain whether hyperbaric oxygenation (HBO) treatment with or without antineoplastic chemotherapy can really suppress tumor development in N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced bladder tumor in rats. HBO treatment of 2 ATA of air saturating with 30-35% of oxygen for 90 min daily plus 0.5 mg/100 g body weight of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) administration for 5 times suppressed the neoplastic spread of the bladder for 9 weeks and reduced the bladder weight in BBN-treated rats. Similar effects were also obtained in ACNU-treated rats, but to a lesser extent. HBO treatment associated with or without doxorubicin failed to suppress tumor growth in BBN-treated animals. Based on these findings combined with the previous study (part I), HBO treatment associated with ACNU might be available for the treatment of some cases of bladder tumors.
Akiya
T
T
Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Nakada
T
T
Katayama
T
T
Ota
K
K
Chikenji
M
M
Matsushita
T
T
Saito
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002085:Butylhydroxybutylnitrosamine; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006931:Hyperbaric Oxygenation; D008297:Male; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D015376:Nimustine; D002085:Butylhydroxybutylnitrosamine; D004317:Doxorubicin